US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
CASI Pharmaceuticals Inc (CASI)
CASI Pharmaceuticals Inc (CASI) ニュース

CASI

CASI Pharmaceuticals (CASI)

CASI Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CASI

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/15	21 : 00	PR Newswire (US)	CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2024/05/15	19 : 50	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CASI	CASI Pharmaceuticals Inc
2024/05/14	21 : 00	PR Newswire (US)	CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS	NASDAQ:CASI	CASI Pharmaceuticals Inc
2024/05/13	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CASI	CASI Pharmaceuticals Inc
2024/04/09	06 : 00	PR Newswire (US)	CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS	NASDAQ:CASI	CASI Pharmaceuticals Inc
2024/03/28	20 : 00	PR Newswire (US)	CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS	NASDAQ:CASI	CASI Pharmaceuticals Inc
2024/03/05	21 : 00	PR Newswire (US)	CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	NASDAQ:CASI	CASI Pharmaceuticals Inc
2024/02/16	21 : 00	PR Newswire (US)	CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/11/14	21 : 00	PR Newswire (US)	CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/11/08	21 : 00	PR Newswire (US)	CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/08/11	20 : 00	PR Newswire (US)	CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/08/01	20 : 00	PR Newswire (US)	Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/07/20	21 : 00	PR Newswire (US)	CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/05/17	20 : 35	PR Newswire (US)	CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/04/26	22 : 49	PR Newswire (US)	CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/04/26	21 : 27	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/04/26	20 : 00	PR Newswire (US)	CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/03/22	19 : 04	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(g) (15-12g)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/03/22	06 : 08	Edgar (US Regulatory)	Post-effective Amendment to an S-8 Filing (s-8 Pos)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/03/22	05 : 51	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/03/22	05 : 42	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/03/22	05 : 30	PR Newswire (US)	CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/02/10	00 : 49	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/02/02	00 : 40	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/02/01	06 : 02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2023/01/06	21 : 00	PR Newswire (US)	CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA	NASDAQ:CASI	CASI Pharmaceuticals Inc
2022/12/15	21 : 00	PR Newswire (US)	CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION	NASDAQ:CASI	CASI Pharmaceuticals Inc
2022/11/16	16 : 57	TipRanks	BTIG Sticks to Their Buy Rating for CASI Pharmaceuticals (CASI)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2022/11/15	06 : 04	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CASI	CASI Pharmaceuticals Inc
2022/11/14	21 : 00	PR Newswire (US)	CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS	NASDAQ:CASI	CASI Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:CASI

1 2 3 4 5 6 7 8 9 10 次へ >>

US Dollar vs Yen

JP Morgan Chase

Health Care Select Sector

Energy Select Sector SPDR

Deutsche Telekom (QX)

Gold vs US Dollar

Bank of America

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約